Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Conditions
- Lymphoma Diffuse Large B-cell
- Leukemia and Lymphoma
- Leukemia Relapse
- Lymphoma Receiving CAR-T Therapy
Interventions
- OTHER: Cyclophosphamide (Non-IMP, Lymphodepletion)
- OTHER: Fludarabine (Non-IMP, Lymphodepletion)
- DRUG: Allo-QuadCAR01-T
Sponsor
AvenCell Therapeutics, Inc.
Collaborators